The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | GASTHER2: trastuzumab for advanced gastric cancer

Name: GASTHER2: trastuzumab for advanced gastric cancer
Uploaded: 2020-07-06T00:00:00Z
Duration: 1 min 43 s
Description: Rachel Riechelmann, MD, PhD, AC Camargo Cancer Canter, São Paulo, Brazil, outlines the rationale behind the GASTHER2 (NCT04168931) study evaluating trastuzumab for patients with advanced gastric cancer with HER2 positive expression in circulating tumour cells. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Rachel Riechelmann • 6 Jul 2020

ESMO WCGIC 2020

Gastric Cancer Gastrointestinal Cancer Antibodies Trastuzumab

GASTHER2

Rachel Riechelmann, MD, PhD, AC Camargo Cancer Canter, São Paulo, Brazil, outlines the rationale behind the GASTHER2 (NCT04168931) study evaluating trastuzumab for patients with advanced gastric cancer with HER2 positive expression in circulating tumour cells. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).